
GUTS Stock Forecast & Price Target
GUTS Analyst Ratings
Bulls say
Fractyl Health Inc. is positioned positively within the metabolic therapeutics sector, particularly as prescriptions for GLP-1 drugs to treat obesity have surged by 587% from 2019 to 2024, indicating increasing market demand. The company’s focus on developing durable, disease-modifying therapies that target the root causes of type 2 diabetes and obesity aligns with emerging trends in healthcare that favor effective long-term solutions over symptomatic management. Additionally, Fractyl Health's anticipated advances in manufacturing capabilities and the promising results from their GLP-1 PGTx program, which show greater improvements in blood glucose and weight control compared to existing treatments, further enhance the company's growth potential.
Bears say
Fractyl Health Inc. exhibits a negative financial outlook primarily due to concerns surrounding its significant cash burn, which may worsen with the expansion of development and commercial programs. Although there were reductions in HbA1c and fat mass measurements, the underlying challenge remains with type 2 diabetes patients facing progressive β-cell dysfunction, necessitating ongoing therapeutic interventions and limiting market potential. Moreover, while potential collaborations could provide milestone revenue, the instability of cash flow and reliance on external partnerships could pose substantial risks to the company's financial health and sustainability.
This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GUTS Analyst Forecast & Price Prediction
Start investing in GUTS
Order type
Buy in
Order amount
Est. shares
0 shares